CLDF Title
Home | Contact Us | Bookmark
    HCC   HE   HRS   NASH   PBC   THROMBOCYTOPENIA  
Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information: AbbVie, Enanta drug shows potential in hep C genotype 4 patients

AbbVie, Enanta drug shows potential in hep C genotype 4 patients

Last Updated: 2014-11-11

By Reuters Staff

(Reuters) - AbbVie Inc said its experimental drug ABT-450 that treats genotype 4 hepatitis C showed high response rates in a mid-stage study in patients who have been considered difficult to treat.

The company is developing the drug with Enanta Pharmaceuticals Inc.

AbbVie's proposed all-oral antiviral treatment consists of the fixed-dose combination of ABT-450/ritonavir (150/100mg) co-formulated with ombitasvir (25mg) dosed once daily, co-administered with weight-based ribavirin (1000mg or 1200mg in divided doses twice daily).

The combination of two direct-acting antivirals, each with distinct mechanisms of action, targets and inhibits specific HCV proteins in the viral replication process, the company said.

At the American Association for the Study of Liver Diseases meeting underway in Boston, the company said 100% of the patients who were given the treatment and had failed previous treatment with pegylated interferon and ribavirin showed high response rates at 12 weeks after the treatment.

Genotype 4 variant of the hepatitis C virus is more frequent in the Middle East and Africa, affecting about 34 million people across the world.

AbbVie also presented data from another mid-stage study where patients infected with both genotype 1 hepatitis C and HIV viruses showed response rates of 93.5% and 90.6% after 12 and 24 weeks post-treatment, respectively.

 
 
 
 
                               
 
HEPATITIS
HBV
HCV
HDV
 
 
HCC
Slide Library
Abstract Library
 
HE
Webcasts
Slide Library
Abstract Library
 
HRS
Webcasts
Slide Library
Abstract Library
 
NASH
Webcasts
Slide Library
Abstract Library
 
 
PBC
Webcasts
Slide Library
Abstract Library
 
 
THROMBOCYTOPENIA
Webcasts
Slide Library
   
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors/Faculty
2019 GI Fellow Board of Advisors
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Hepatology
Substance Use Disorder
             
CLDF Follow Us
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2019 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.